At Arcus Biosciences, we are committed to creating innovative cancer immunotherapies. While the field of immuno-oncology (or cancer immunotherapy) has exploded in the past decade, the unfortunate reality is that a large segment of patients fails to benefit from such medicines. As such, there remains a significant unmet medical need.
As part of our commitment, we are focused on conducting clinical trials of our investigational medicines in order to demonstrate their safety and efficacy in cancer patients. It is only through these clinical trials and the generation of safety and efficacy data to support any application for regulatory approval that we can have the greatest impact on the patients whom our medicines are designed to benefit. Given the early stages of our clinical trials, we do not have an expanded access program at this time.
We believe, patients who choose to participate in clinical trials play a critical role in developing new medicines. If you are interested in gaining access to our investigational medicines, we encourage you to speak with your physician about the possibility of enrolling in one of our clinical trials.
The following clinical trials for Arcus’s product candidates are currently enrolling:
A Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).
A Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AB928 in combination with pegylated liposomal doxorubicin (PLD) in participants with advanced metastatic triple-negative breast cancer or ovarian cancer.
A Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD and clinical activity of AB928 in combination with AB122 in participants with advanced malignancies.
This is a double-blind, randomized, placebo-controlled, single-ascending dose study to investigate the safety, tolerability, and pharmacokinetic profile of AB680 in healthy volunteers.
A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors.
A Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with AB122 in participants with advanced solid malignancies.